[go: up one dir, main page]

MX2015010728A - Metodos y composiciones para el tratamiento de leucemia. - Google Patents

Metodos y composiciones para el tratamiento de leucemia.

Info

Publication number
MX2015010728A
MX2015010728A MX2015010728A MX2015010728A MX2015010728A MX 2015010728 A MX2015010728 A MX 2015010728A MX 2015010728 A MX2015010728 A MX 2015010728A MX 2015010728 A MX2015010728 A MX 2015010728A MX 2015010728 A MX2015010728 A MX 2015010728A
Authority
MX
Mexico
Prior art keywords
compositions
leukemia
methods
treatment
present
Prior art date
Application number
MX2015010728A
Other languages
English (en)
Inventor
Sheng-Yung Liu
Wu-Che Wen
Chih-Ming Chen
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Publication of MX2015010728A publication Critical patent/MX2015010728A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención provee métodos y composiciones para tratar leucemia mediante compuestos de ciclohexenona.
MX2015010728A 2013-02-20 2014-02-20 Metodos y composiciones para el tratamiento de leucemia. MX2015010728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767211P 2013-02-20 2013-02-20
PCT/US2014/017285 WO2014130619A2 (en) 2013-02-20 2014-02-20 Methods and compositions for treating leukemia

Publications (1)

Publication Number Publication Date
MX2015010728A true MX2015010728A (es) 2016-04-11

Family

ID=51391965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010728A MX2015010728A (es) 2013-02-20 2014-02-20 Metodos y composiciones para el tratamiento de leucemia.

Country Status (16)

Country Link
US (1) US9403747B2 (es)
EP (1) EP2958558B1 (es)
JP (1) JP6501123B2 (es)
KR (1) KR102054038B1 (es)
CN (2) CN108309961A (es)
AU (1) AU2014218938B2 (es)
BR (1) BR112015019924A2 (es)
CA (1) CA2901745A1 (es)
DK (1) DK2958558T3 (es)
ES (1) ES2687286T3 (es)
HK (2) HK1219884A1 (es)
MX (1) MX2015010728A (es)
PL (1) PL2958558T3 (es)
TW (1) TWI597061B (es)
WO (1) WO2014130619A2 (es)
ZA (1) ZA201506330B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069448B (zh) * 2016-02-17 2021-09-21 国鼎生物科技股份有限公司 用于治疗肝癌的组合物和方法
AU2017261826B2 (en) * 2016-05-13 2022-09-29 Golden Biotechnology Corporation Methods and compositions for treating advanced stage non-small cell lung cancer
TWI601535B (zh) * 2016-06-23 2017-10-11 台灣利得生物科技股份有限公司 牛樟段木栽培牛樟芝子實體及固態培養菌絲體水及乙醇萃取物之組合物應用於抗癌藥輔助劑
CN107540641A (zh) * 2016-06-29 2018-01-05 彭朗 一种新的有机酯类化合物及其制备方法和医药用途
US10314241B1 (en) * 2016-09-14 2019-06-11 T. Scott Dunn Airborne vegetation cutting assembly
US11406605B2 (en) * 2017-12-20 2022-08-09 Golden Biotechnology Corporation Therapeutic compositions for treating pancreatic cancer
EP3930724B1 (en) * 2019-02-25 2024-07-03 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
US11548069B2 (en) 2019-05-20 2023-01-10 Wisconsin Alumni Research Foundation Three-dimensional printer laminating fusible sheets

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US20070287672A1 (en) * 2004-04-20 2007-12-13 Donald Creighton Macromolecular Gsh-Activiated Glyoxylase I Inhibitors
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
CN101343247B (zh) * 2007-07-12 2011-01-19 国鼎生物科技股份有限公司 牛樟芝的环己烯酮萃取物
TW200918498A (en) * 2007-10-19 2009-05-01 Golden Biotechnology Corp Novel compound isolated from Antrodia camphorate extracts
TWI389699B (zh) 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
TW201102075A (en) * 2009-07-09 2011-01-16 Golden Biotechnology Corp Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer
TW201109013A (en) * 2009-09-09 2011-03-16 Golden Biotechnology Corp Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of the Lymphoma tumor cell
ES2574606T3 (es) 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
CN102232942B (zh) * 2010-05-06 2013-03-27 国鼎生物科技股份有限公司 用于抑制淋巴癌肿瘤细胞生长的牛樟芝环己烯酮化合物
US8309611B2 (en) * 2010-09-20 2012-11-13 Golden Biotechnology Corporation Methods and compositions for treating lung cancer
AU2011336882A1 (en) * 2010-11-24 2013-06-20 Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
TWI444189B (zh) * 2011-05-31 2014-07-11 Mackay Memorial Hospital 羊毛甾醇－８，２４－二烯－３β，１５α，２１－三醇抑制腫瘤細胞生長之用途
KR20140102599A (ko) * 2011-06-10 2014-08-22 골든 바이오테크놀러지 코포레이션 뇌암 치료를 위한 방법 및 조성물
TWI484954B (zh) * 2011-10-11 2015-05-21 New Bellus Entpr Co Ltd 用於治療癌症之醫藥組合物
WO2014151304A1 (en) * 2013-03-15 2014-09-25 Golden Biotechnology Corporation Therapeutic methods and compositions utilizing cyclohexenone compounds

Also Published As

Publication number Publication date
BR112015019924A2 (pt) 2017-07-18
TWI597061B (zh) 2017-09-01
JP2016509058A (ja) 2016-03-24
WO2014130619A3 (en) 2014-10-16
JP6501123B2 (ja) 2019-04-17
ZA201506330B (en) 2016-10-26
TW201446240A (zh) 2014-12-16
CN105246470A (zh) 2016-01-13
EP2958558A2 (en) 2015-12-30
PL2958558T3 (pl) 2018-12-31
AU2014218938B2 (en) 2018-12-06
DK2958558T3 (en) 2018-09-24
WO2014130619A2 (en) 2014-08-28
KR20150120424A (ko) 2015-10-27
HK1255453A1 (zh) 2019-08-16
US9403747B2 (en) 2016-08-02
EP2958558B1 (en) 2018-06-13
CA2901745A1 (en) 2014-08-28
KR102054038B1 (ko) 2019-12-09
US20150025135A1 (en) 2015-01-22
EP2958558A4 (en) 2016-08-10
AU2014218938A1 (en) 2015-09-10
ES2687286T3 (es) 2018-10-24
CN108309961A (zh) 2018-07-24
HK1219884A1 (zh) 2017-04-21

Similar Documents

Publication Publication Date Title
NI201700071A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
UY37018A (es) Inhibidores bicíclicos de pad4
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
CR20150517A (es) Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il) nicotinamida
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
ECSP16074207A (es) Pirazinas moduladoras de gpr6